New microbial strain produces high yields of lutein for AMD, cataract prevention

News
Article

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

A row of beakers with yellow and orange fluid in a laboratory. Concept image for microbial lutein production, bioengineering, sustainable synthesis for cataract cornea age-related macular degeneration (AMD) and retinal disease. Image credit: bidala – stock.adobe.com

Lutein, an antioxidant, is known to assist in the prevention of age-related macular degeneration and cataracts. Image credit: bidala – stock.adobe.com

Researchers at the Korea Advanced Institute of Science and Technology (KAIST) announced the development of a safe, high-yield microbial strain capable of more efficiently producing lutein compared to conventional methods.1

Lutein is an antioxidant known to prevent age-related macular degeneration (AMD) and cataracts. Conventional methods of obtaining lutein include extraction from marigolds or microalgae, which is often slow, costly and challenging to industrialise due to limited resources. KAIST’s new approach offers an eco-friendly and scalable alternative.1

A study led by Lee Sang-yup of the Department of Chemical and Bimolecular Engineering was published in the journal Nature Synthesis and demonstrated the potential of microbial metabolic engineering to mass-produce valuable health-related compounds using sustainable processes.1

“This research overcomes the production bottlenecks in microbial lutein synthesis and establishes a competitive, eco-friendly process,” Eun Hyun-min, a doctoral student and co-first author of the paper, said in a press release. “We expect this to help accelerate the practical use of microbial platforms for producing various natural compounds.”

Focusing on Corynebacterium glutamicum, a microorganism widely recognised as safe for food and pharmaceutical use, and applying a technique known as electron channeling KAIST modified the strain’s internal metabolic pathways. This modification accelerated the chemical reactions needed to produce lutein.

Optimizing enzyme arrangement and enhancing electron transfer allowed the KAIST research team to achieve a production rate of 1.78 grams per liter in 54 hours. This translates to an average of 32.88 milligrams per liter per hour, which significantly outperforms conventional extraction methods.

Researchers used glucose to feed the microbe. Glucose, a common and renewable sugar source, not only enhanced production efficiency, but it also supported a more sustainable manufacturing process.1

“Microbial metabolic engineering is emerging as a next-generation strategy that goes beyond traditional plant-based or chemical synthesis,” Sang-yup said in a press release. “We will continue researching ways to produce high-value natural substances more efficiently using microorganisms.”

South Korea’s Ministry of Science and ICT funded the work as part of a national initiative. Sang-yup’s startup, Silico Bio, is expected to commercialise the technology.

Reference:

  1. Park Sae-jin. KAIST team develops microbe for efficient, eco-friendly lutein production | AJU PRESS. AJU PRESS. Published July 13, 2025. Accessed July 14, 2025. https://www.ajupress.com/view/20250713153815898

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.